A high burden of cytomegalovirus marks poor vascular health in transplant recipients more clearly than in the general population.
cytomegalovirus
inflammatory biomarkers
transplantation
vascular pathology
Journal
Clinical & translational immunology
ISSN: 2050-0068
Titre abrégé: Clin Transl Immunology
Pays: Australia
ID NLM: 101638268
Informations de publication
Date de publication:
2019
2019
Historique:
received:
20
11
2018
revised:
07
01
2019
accepted:
08
01
2019
entrez:
22
2
2019
pubmed:
23
2
2019
medline:
23
2
2019
Statut:
epublish
Résumé
Meta-analyses have now confirmed that persistent infections with cytomegalovirus (CMV) can accelerate the onset of diseases of ageing, notably cardiovascular pathologies. We address the circumstances in which the association may be strong enough to warrant intervention to reduce the viral burden. We compare markers of the burden of CMV with established indices of vascular pathology in healthy adults ( Carotid intima-media thickness, FMD, eGFR and plasma levels of CMV antibodies (reactive with a lysate, CMV IE-1 or CMV gB), ICAM-1, VCAM-1, P-selectin, sIFNαR2, sTNFR1, sCD14 and CRP were determined. Levels of CMV antibody predict declining endothelial health in RTR and not in healthy adults, presumably by reflecting a high burden of CMV. The levels of CMV antibodies were a poor reflection of plasma biomarkers thought to reflect 'inflammaging' or vascular damage.
Identifiants
pubmed: 30788107
doi: 10.1002/cti2.1043
pii: CTI21043
pmc: PMC6369563
doi:
Types de publication
Journal Article
Langues
eng
Pagination
e1043Références
J Am Coll Cardiol. 1999 Nov 15;34(6):1738-43
pubmed: 10577564
Transplantation. 2000 Mar 27;69(6):1160-8
pubmed: 10762222
Clin Exp Immunol. 2000 May;120(2):333-7
pubmed: 10792384
Virology. 2000 Jul 5;272(2):357-65
pubmed: 10873779
J Am Coll Cardiol. 2002 Jan 16;39(2):257-65
pubmed: 11788217
Neurobiol Dis. 2002 Feb;9(1):82-7
pubmed: 11848687
Circulation. 2003 Jan 21;107(2):251-7
pubmed: 12538424
J Virol Methods. 2003 Apr;109(1):1-9
pubmed: 12668261
Transplantation. 2003 Jun 15;75(11):1858-64
pubmed: 12811246
Vaccine. 2003 Sep 8;21(25-26):3826-36
pubmed: 12922116
Exp Gerontol. 2007 Jun;42(6):563-70
pubmed: 17337145
Curr Top Microbiol Immunol. 2008;325:63-83
pubmed: 18637500
J Mol Med (Berl). 2009 Apr;87(4):347-56
pubmed: 19083194
Int J Epidemiol. 2009 Jun;38(3):775-87
pubmed: 19109247
Rev Med Virol. 2010 Jul;20(4):202-13
pubmed: 20564615
J Infect Dis. 2010 Sep 1;202(5):690-9
pubmed: 20632887
Lancet. 2012 Jun 2;379(9831):2053-62
pubmed: 22541275
Aging Cell. 2012 Oct;11(5):912-5
pubmed: 22708923
Clin J Am Soc Nephrol. 2012 Dec;7(12):2058-70
pubmed: 22977217
Lancet Infect Dis. 2012 Oct;12(10):790-8
pubmed: 23017365
J Infect Dis. 2013 May 15;207(10):1569-75
pubmed: 23417659
Eur J Heart Fail. 2014 Jan;16(1):86-94
pubmed: 23901055
Geriatr Gerontol Int. 2016 Jan;16(1):21-7
pubmed: 25496508
Clin J Am Soc Nephrol. 2015 Sep 4;10(9):1525-33
pubmed: 26153127
J Clin Immunol. 2016 Feb;36(2):113-6
pubmed: 26759253
J Med Virol. 2017 Jan;89(1):177-181
pubmed: 27312237
Virus Res. 2017 Jan 2;227:124-134
pubmed: 27664838
Mech Ageing Dev. 2017 Jul;165(Pt B):129-138
pubmed: 28038993
Clin Immunol. 2018 Feb;187:107-112
pubmed: 29108855
J Med Virol. 1994 Feb;42(2):170-4
pubmed: 8158112
Microbiol Immunol. 1997;41(2):121-9
pubmed: 9087954